8-K 1 a19-12550_48k.htm 8-K





Washington, D.C. 20549



Form 8-K




Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported)

July 9, 2019


Commission File Number: 001-36568











(State or other jurisdiction of
incorporation or organization)


(Primary Standard Industrial
Classification Code Number)


(I.R.S. Employer
Identification Number)


15 West Scenic Pointe Drive

Suite 100

Draper, Utah 84020

(801) 727-1000

(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant’s Principal Executive Offices)


Not Applicable

(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):


o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company o


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Securities registered pursuant to Section 12(b) of the Act:


Title of each class


Trading Symbol(s)


Name of each exchange on which registered

Common stock, par value $0.0001 per share




The NASDAQ Global Select Market





Item 1.01              Entry into a Definitive Material Agreement


On July 9, 2019, HealthEquity, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Wells Fargo Securities, LLC and the other several underwriters named therein (the “Underwriters”).  Pursuant to the terms of the Underwriting Agreement, the Company agreed to sell, and the Underwriters agreed to purchase, subject to and on the conditions set forth therein, an aggregate of 6,750,000 shares of the Company’s common stock.  The Company has also granted the Underwriters an option to purchase up to an additional 1,012,500 shares of the Company’s common stock. The Company estimates that the net proceeds from the offering will be approximately $398.4 million, or approximately $458.3 million if the Underwriters exercise in full their option to purchase additional shares of the Company’s common stock after deducting the estimated discount to the Underwriters and the related fees and expenses of the offering.


The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions.


The offering is being made pursuant to the Company’s effective shelf registration statement (the “Registration Statement”) on Form S-3 (Registration No. 333-227231), including the prospectus supplement dated July 8, 2019 and the prospectus supplement dated July 9, 2019.


The Underwriting Agreement is filed as Exhibit 1.1 to this Current Report on Form 8-K and incorporated herein by reference. The above description is qualified in its entirety by reference to such exhibit.


The Underwriters have provided in the past to the Company, and may provide from time to time in the future, certain commercial banking, financial advisory, investment banking and other services in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions. Wells Fargo Securities, LLC also acted as an underwriter in connection with the underwritten public offering of the Company’s common stock in May 2015 and lender in connection with the funding of the Company’s existing senior credit facilities. Wells Fargo Securities, LLC has also acted as the Company’s financial adviser in connection with the previously announced agreement and plan of merger entered into between the Company, WageWorks, Inc. and Pacific Merger Sub Inc., a wholly owned subsidiary of the Company, to acquire all of the outstanding shares of common stock of WageWorks, Inc. for cash (the “Merger”). We have also granted certain of the Underwriters the right to participate in any public or private offering of securities by the Company relating to the Merger, subject to certain limitations.


Item 9.01              Financial Statements and Exhibits


Exhibit No.








Underwriting Agreement, dated as of July 9, 2019, by and among HealthEquity, Inc., Wells Fargo Securities, LLC and the other several underwriters named therein




Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.










/s/ Darcy Mott



Darcy Mott



Executive Vice President and Chief Financial Officer



Dated: July 11, 2019